Pharmacokinetics of an extended-release theophylline product in cats

Christine L. Guenther-Yenke, Brendan C. McKiernan, Mark G. Papich, Elizabeth Powell

Research output: Contribution to journalArticlepeer-review

Abstract

Objective - To evaluate the pharmacokinetics of a brand of extended-release theophylline tablets and capsules in healthy cats. Design - Randomized 3-way crossover study. Animals - 6 healthy cats. Procedures - A single dose of aminophylline (10 mg/kg [4.5 mg/lb], IV), a 100-mg extended-release theophylline tablet, or a 125-mg extended-release theophylline capsule was administered to all cats. Plasma samples were collected via preplaced central catheters throughout a 36-hour period. Plasma samples were frozen until analyzed by use of a fluorescence polarization monoclonal immunoassay. Results - All cats tolerated drug administration and plasma collection with no adverse effects. Peak concentrations were reached for both orally administered products between 8 and 12 hours after administration. Bioavailability was excellent. Plasma concentrations were within the human therapeutic concentration of 5 to 20 μg/mL. Conclusions and Clinical Relevance - Daily administration of the brand of theophylline tablets and capsules used in this study at 15 mg/kg (6.8 mg/lb) and 19 mg/kg (8.6 mg/lb), respectively, maintained plasma concentrations within the desired therapeutic range in healthy cats.

Original languageEnglish (US)
Pages (from-to)900-906
Number of pages7
JournalJournal of the American Veterinary Medical Association
Volume231
Issue number6
DOIs
StatePublished - Sep 15 2007

ASJC Scopus subject areas

  • veterinary(all)

Fingerprint Dive into the research topics of 'Pharmacokinetics of an extended-release theophylline product in cats'. Together they form a unique fingerprint.

Cite this